Meda

Meda (Buy) 14-05-2013
A group of scientists that includes the chairman of the European allergy committee has published additional analysis of the Phase III results on Meda’s allergy drug Dymista. The authors conclude that Dymista provides clinical relevance and not only met its primary endpoint in the study. We expect European guidelines to include Dymista shortly. Buy, 12M TP SEK100.

Skriv et svar